000110843 001__ 110843
000110843 005__ 20240319081001.0
000110843 0247_ $$2doi$$a10.3389/fmed.2022.799355
000110843 0248_ $$2sideral$$a127713
000110843 037__ $$aART-2022-127713
000110843 041__ $$aeng
000110843 100__ $$0(orcid)0000-0002-1275-2600$$aSantander Ballestín, Sonia$$uUniversidad de Zaragoza
000110843 245__ $$aAntitumor Anesthetic Strategy in the Perioperatory Period of the Oncological Patient: A Review
000110843 260__ $$c2022
000110843 5060_ $$aAccess copy available to the general public$$fUnrestricted
000110843 5203_ $$aThe stress response triggered by the surgical aggression and the transient immunosuppression produced by anesthetic agents stimulate the inadvertent dispersion of neoplastic cells and, paradoxically, tumor progression during the perioperative period. Anesthetic agents and techniques, in relation to metastatic development, are investigated for their impact on long-term survival. Scientific evidence indicates that inhaled anesthetics and opioids benefit immunosuppression, cell proliferation, and angiogenesis, providing the ideal microenvironment for tumor progression. The likely benefit of reducing their use, or even replacing them as much as possible with anesthetic techniques that protect patients from the metastatic process, is still being investigated. The possibility of using “immunoprotective” or “antitumor” anesthetic techniques would represent a turning point in clinical practice. Through understanding of pharmacological mechanisms of anesthetics and their effects on tumor cells, new perioperative approaches emerge with the aim of halting and controlling metastatic development. Epidural anesthesia and propofol have been shown to maintain immune activity and reduce catecholaminergic and inflammatory responses, considering the protective techniques against tumor spread. The current data generate hypotheses about the influence of anesthesia on metastatic development, although prospective trials that determinate causality are necessary to make changes in clinical practice.
000110843 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000110843 590__ $$a3.9$$b2022
000110843 592__ $$a0.926$$b2022
000110843 591__ $$aMEDICINE, GENERAL & INTERNAL$$b58 / 169 = 0.343$$c2022$$dQ2$$eT2
000110843 593__ $$aMedicine (miscellaneous)$$c2022$$dQ1
000110843 594__ $$a3.6$$b2022
000110843 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000110843 700__ $$aLanuza Bardaji, Andrea
000110843 700__ $$aMarco Continente, Cristina
000110843 700__ $$0(orcid)0000-0003-4071-1467$$aLuesma Bartolomé, María José$$uUniversidad de Zaragoza
000110843 7102_ $$11003$$2027$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Anatom.Embriol.Humana
000110843 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000110843 773__ $$g9 (2022), 799355 [16 pp]$$pFront. med.$$tFrontiers in Medicine$$x2296-858X
000110843 8564_ $$s1058825$$uhttps://zaguan.unizar.es/record/110843/files/texto_completo.pdf$$yVersión publicada
000110843 8564_ $$s2337238$$uhttps://zaguan.unizar.es/record/110843/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000110843 909CO $$ooai:zaguan.unizar.es:110843$$particulos$$pdriver
000110843 951__ $$a2024-03-18-14:12:15
000110843 980__ $$aARTICLE